Naoto Ueno, Director of the University of Hawaii Cancer Center, shared a post on LinkedIn:
” ‘NIH R01 Kickoff Meeting: Developing a Novel Antibody – Drug Conjugate for Cancer Therapy’
I am grateful that our team has received NIH R01 funding to develop a novel antibody – drug conjugate (ADC) for cancer therapy. Today, we held our first kickoff meeting, bringing together a strong multidisciplinary team with expertise in antibody engineering, cancer biology, clinical investigation, medicinal chemistry, linker chemistry, and translational drug development.
This project is meaningful because it reflects the kind of team science needed to create a new cancer therapy from the ground up. The antibody, linker, payload strategy, tumor biology, and clinical vision all need to come together with rigor and purpose.
Our goal is not simply to develop another ADC, but to build a therapeutic approach that is biologically sound, clinically relevant, and ultimately meaningful for patients.
I am very excited to work with this outstanding team, including Jennifer Maynard, Henry Beckman Professor in Chemical Engineering at The University of Texas at Austin, Kyoji Tsuchikama, Associate Professor at UTHealth Houston, whose work focuses on medicinal chemistry and linker chemistry, McKenna Flynn from The University of Texas at Austin, Zhaoxuan Yang from UTHealth Houston, Jangsoon Lee from the University of Hawai’i Cancer Center, Minji Seo from the UHCC and Samuel Cirigliano from The University of Texas at Austin.
This is exactly the kind of collaboration that can move an idea from discovery to drug development, and eventually toward impact for patients with cancer.”
Naoto Ueno/ LinkedIn
Other Articles Featuring Naoto Ueno on OncoDaily.